Lenalidomide Hemihydrate is a thalidomide derivative and immunomodulatory agent primarily indicated for the treatment of multiple myeloma and anemia associated with low- to intermediate-risk myelodysplastic… Read more
Lenalidomide Hemihydrate is a thalidomide derivative and immunomodulatory agent primarily indicated for the treatment of multiple myeloma and anemia associated with low- to intermediate-risk myelodysplastic syndromes. As pharmaceutical laboratories perform rigorous quality control and impurity profiling, high-quality reference standards become essential for accurate analysis. This category provides access to Lenalidomide Hemihydrate and its related compounds, including pharmacopeial and non-pharmacopeial impurities, degradation products, and metabolites. These materials are critical for the development and validation of analytical methods such as HPLC and mass spectrometry, ensuring regulatory compliance and precise identification of unknown peaks. Additionally, stable isotope-labelled versions of this compound serve as internal standards, facilitating accurate quantification during pharmacokinetic studies and complex bioanalytical method development. By utilizing these precise reference materials, researchers can maintain the highest standards in drug development and manufacturing consistency.